A single-arm, nonrandomized phase II study of talazoparib (NEOTALA) assessed patients with germline BRCA1/2 mutations and locally advanced HER-2-negative breast cancer (tumor size at least 1.5 cm) [19]. This evidence concerns the gene ERBB2 and neoplasm.